Skip to content
Open access

Non-cancer causes of death following cervical cancer diagnosis: a SEER database study.

Oct 2026 · Journal of Gynecologic Oncology · Vol 38 · 0 citations · 21 references
Medicine

TL;DR

Non-cancer mortality remains elevated among cervical cancer survivors, including beyond the 5-year landmark, and treatment-group contrasts are strongly affected by disease stage, treatment-selection mechanisms, and unmeasured clinical factors; they should be interpreted as hypothesis-generating rather than causal.

Abstract

Objective

To quantify non-cancer mortality after cervical cancer diagnosis and examine how these risks vary over time, by disease stage, race, and registry-recorded treatment patterns.

Methods

We analyzed 65,852 women diagnosed with cervical cancer in Surveillance, Epidemiology, and End Results-17 (2000-2021). Standardized mortality ratios (SMRs) compared observed deaths with age-, race-, sex-, and calendar-period-specific mortality in the U.S. general population. Fine-Gray models retained every death other than the target cause as a competing event.

Results

Of 24,857 deaths, 19,975 (80.4%) were cancer-related and 4,882 (19.6%) were non-cancer-related. The overall non-cancer SMR was 1.65 (95% confidence interval [CI]=1.60-1.70). After International Federation of Gynecology and Obstetrics stage- and race-exact propensity score matching (4,506 pairs; maximum absolute standardized mean difference, 0.079), registry-inferred combined radiotherapy plus chemotherapy without surgery was not associated with overall non-cancer death (subdistribution hazard ratio [sHR]=1.01; 95% CI=0.88-1.16); the infectious-disease (sHR=1.72; 95% CI=0.75-3.95) and septicemia estimates (sHR=1.60; 95% CI=0.69-3.72; 23 events) were imprecise. Among 31,617 patients surviving beyond 5 years, the conditional non-cancer SMR remained elevated (1.44; 95% CI=1.38-1.49).

Conclusion

Non-cancer mortality remains elevated among cervical cancer survivors, including beyond the 5-year landmark. Treatment-group contrasts are strongly affected by disease stage, treatment-selection mechanisms, and unmeasured clinical factors; they should therefore be interpreted as hypothesis-generating rather than causal. Survivorship care should integrate cardiovascular, infectious, renal, respiratory, and metabolic risk management.

Read PDF

Similar papers

Review Oct 2026

Uterine Cervix Cancer—20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration, Selected ICD-O-3 Histologic Oncophenotypes, and Cohort Entry Time Period: A Systematic Review of 45,213 Cases for Diagnosis Years 1975-2023

.—Globally, cervical cancer is the fourth most common cancer in women with 604,127 new cases and 341,837 related deaths in 2022. The primary risk factor for cervical cancer is human papillomavirus (HPV) infection, especially by HPV subtypes 16 and 18. In 2019, HPV caused an estimated 620,000 cancer cases in women a...

Anthony F. Milano · 0 citations
Open access Nov 2026

Feature of esophageal cancer mortality in USA from 1999 to 2023: based on CDC WONDER database

Esophageal cancer remains a highly lethal malignancy with substantial mortality burden in the United States. Previous studies struggle to track the latest demographic and regional characteristics of esophageal cancer. Therefore, updated data are urgently needed for disease control and develop health policies....

Ming-Feng Wei, Shi-Xian Guo, Xiao-Yu Chen et al. · 0 citations
Nov 2026

Trends in breast, cervical, and colon cancer incidence and mortality rates in Türkiye: national evaluation of three population-based screening-targeted cancers.

Breast, cervical, and colon cancer are central to cancer control policy in Türkiye, yet their long-term incidence and mortality trends have not been described with formal trend-segmentation methods. We conducted a population-based Joinpoint regression analysis of age-standardized incidence (2009-2020; registry coverage...

Güven Turan, Merve Turan, Yasemin Başpınar et al. · 0 citations
Open access Nov 2026

Development and Internal Validation of a Competing-Risk Nomogram for Predicting Cancer-Specific Death in Oral Cavity Squamous Cell Carcinoma.

OBJECTIVE Oral cavity squamous cell carcinoma (OCSCC) patients face competing risks of cancer and non-cancer death. This study developed and internally validated a competing-risk nomogram for cancer-specific death. METHODS A total of 84,456 SEER 17-registry adults (age ≥ 20 years) with OCSCC (2000-2023) were identifi...

Kuan-Yu Chu · 0 citations
Review Dec 2026

Endometrial Uterine Cancer—20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration, Selected ICD-O-3 Histologic Oncophenotypes, and Cohort Entry Time Period: A Systematic Analysis of 155,218 Cases for Diagnosis Years 1975-2023

This study encompasses a review of 155,218 cases from 1975 to 2023 using the National Cancer Institute’s Surveillance, Epidemiology, and End Results 8 Registry. Endometrial cancer is the most common gynecologic malignancy in the United States and accounts for 7% of all cancers in women. In 2026, the estimated number of...

Anthony F. Milano · 0 citations
Open access Oct 2026

Assessment of cardiovascular disease-associated mortality risk among early-stage breast cancer patients

This is one of the first studies to identify an approximate mortality crossover point between CSM and BC-specific mortality at about 8 years (97 months) in women aged 70–85, providing a clinically relevant, exploratory time point for increased cardiovascular monitoring in this high-risk population.

Ndagijimana Djuma, E. Fiagbey, E. Iweh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.